Page last updated: 2024-11-08

validamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

validamine: RN given from CA Index Guide; RN not in Chemline 11/84; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

validamine : An amino cyclitol consisting of 1D-chiro-inositol lacking the 6-hydroxy group and having those at positions 1 and 5 replaced by amino and hydroxymethyl groups respectively. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID446685
CHEMBL ID1628264
CHEBI ID30449
SCHEMBL ID5793335
MeSH IDM0126491

Synonyms (20)

Synonym
AC-4499
d-chiro-inositol, 1-amino-1,5,6-trideoxy-5-(hydroxymethyl)-
validamine
CHEBI:30449 ,
1d-1-amino-1,5,6-trideoxy-5-(hydroxymethyl)-chiro-inositol
32780-32-8
(1r,2s,3s,4s)-4-amino-6-(hydroxymethyl)cyclohexane-1,2,3-triol
1-amino-1,5,6-trideoxy-5-(hydroxymethyl)-d-chiro-inositol
(+)-validamine
(1r,2s,3s,4s,6r)-4-amino-6-(hydroxymethyl)cyclohexane-1,2,3-triol
CHEMBL1628264 ,
AKOS006284984
A821410
bdbm50367332
SCHEMBL5793335
Q27113564
4-amino-6-(hydroxymethyl)cyclohexane-1,2,3-triol
DTXSID60954439
HY-N2383
CS-0022551
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino cyclitolAny cyclitol having one or more alcoholic hydroxy groups replaced by substituted or unsubstituted amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Maltase-glucoamylase, intestinalHomo sapiens (human)IC50 (µMol)110.00000.04003.46529.0000AID104666
Sucrase-isomaltase, intestinalHomo sapiens (human)IC50 (µMol)7.50000.04902.72947.8000AID208984
Beta-galactosidaseBos taurus (cattle)IC50 (µMol)1,000.00001.50002.70003.6000AID241465
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
sucrose catabolic processSucrase-isomaltase, intestinalHomo sapiens (human)
polysaccharide digestionSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate metabolic processBeta-galactosidaseBos taurus (cattle)
glucosylceramide catabolic processCytosolic beta-glucosidaseHomo sapiens (human)
glucosylceramide catabolic processCytosolic beta-glucosidaseHomo sapiens (human)
galactosylceramide catabolic processCytosolic beta-glucosidaseHomo sapiens (human)
oligosaccharide catabolic processCytosolic beta-glucosidaseHomo sapiens (human)
glycoside catabolic processCytosolic beta-glucosidaseHomo sapiens (human)
glycosphingolipid catabolic processCytosolic beta-glucosidaseHomo sapiens (human)
protein stabilizationCytosolic beta-glucosidaseHomo sapiens (human)
beta-glucoside catabolic processCytosolic beta-glucosidaseHomo sapiens (human)
positive regulation of exo-alpha-sialidase activityCytosolic beta-glucosidaseHomo sapiens (human)
glycosylceramide catabolic processCytosolic beta-glucosidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
oligo-1,6-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
sucrose alpha-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
protein bindingSucrase-isomaltase, intestinalHomo sapiens (human)
carbohydrate bindingSucrase-isomaltase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activitySucrase-isomaltase, intestinalHomo sapiens (human)
beta-galactosidase activityBeta-galactosidaseBos taurus (cattle)
galactosylceramidase activityCytosolic beta-glucosidaseHomo sapiens (human)
glucosylceramidase activityCytosolic beta-glucosidaseHomo sapiens (human)
beta-galactosidase activityCytosolic beta-glucosidaseHomo sapiens (human)
protein bindingCytosolic beta-glucosidaseHomo sapiens (human)
beta-glucosidase activityCytosolic beta-glucosidaseHomo sapiens (human)
glycosylceramidase activityCytosolic beta-glucosidaseHomo sapiens (human)
scopolin beta-glucosidase activityCytosolic beta-glucosidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
Golgi apparatusSucrase-isomaltase, intestinalHomo sapiens (human)
plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
brush borderSucrase-isomaltase, intestinalHomo sapiens (human)
apical plasma membraneSucrase-isomaltase, intestinalHomo sapiens (human)
extracellular exosomeSucrase-isomaltase, intestinalHomo sapiens (human)
lysosomeBeta-galactosidaseBos taurus (cattle)
cytosolCytosolic beta-glucosidaseHomo sapiens (human)
catalytic complexCytosolic beta-glucosidaseHomo sapiens (human)
cytosolCytosolic beta-glucosidaseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID104666Inhibitory activity against porcine maltase1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents.
AID241465Inhibition of Beta-galactosidase of bovine liver; no inhibition2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Synthesis of 5a-carba-hexopyranoses and hexopyranosylamines, as well as 5a,5a'-dicarbadisaccharides, from 3,8-dioxatricyclo[4.2.1.0(2,4)]nonan-9-ol: glycosidase inhibitory activity of N-substituted 5a-carba-beta-gluco- and beta-galactopyranosylamines, and
AID240951Inhibition of Beta-glucosidase of rat intestine2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Synthesis of 5a-carba-hexopyranoses and hexopyranosylamines, as well as 5a,5a'-dicarbadisaccharides, from 3,8-dioxatricyclo[4.2.1.0(2,4)]nonan-9-ol: glycosidase inhibitory activity of N-substituted 5a-carba-beta-gluco- and beta-galactopyranosylamines, and
AID241217Inhibition of Alpha-galactosidase of green coffee beans2004Bioorganic & medicinal chemistry letters, Oct-18, Volume: 14, Issue:20
Synthesis of 5a-carba-hexopyranoses and hexopyranosylamines, as well as 5a,5a'-dicarbadisaccharides, from 3,8-dioxatricyclo[4.2.1.0(2,4)]nonan-9-ol: glycosidase inhibitory activity of N-substituted 5a-carba-beta-gluco- and beta-galactopyranosylamines, and
AID208984Alpha-D-glucosidase inhibitory activity and enzyme inhibition in vitro against porcine sucrase1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (14.29)18.7374
1990's3 (21.43)18.2507
2000's6 (42.86)29.6817
2010's3 (21.43)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.53 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]